Mirostipen Biosimilar – Anti-CD191 – Research Grade

Mirostipen Biosimilar – Anti-CD191: A Promising Therapeutic Antibody Targeting CD191

Mirostipen Biosimilar – Anti-CD191 is a novel biosimilar antibody that has shown promising results in targeting CD191, also known as C-C chemokine receptor type 1 (CCR1). This therapeutic antibody has been extensively researched and has demonstrated potential in the treatment of various inflammatory and autoimmune diseases.

Structure of Mirostipen Biosimilar – Anti-CD191

Mirostipen Biosimilar – Anti-CD191 is a monoclonal antibody, meaning it is produced by a single type of immune cell. It is a humanized antibody, which means it is derived from non-human antibodies but has been modified to be more similar to human antibodies. This modification reduces the risk of immune reactions and increases the efficacy of the antibody.

The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are made up of four constant regions and one variable region, while the light chains have two constant regions and one variable region. The variable regions are responsible for binding to the target molecule, CD191, while the constant regions provide stability and effector functions.

Mechanism of Action

Mirostipen Biosimilar – Anti-CD191 works by binding to CD191, a chemokine receptor that is expressed on the surface of various immune cells. This binding prevents the interaction of CD191 with its ligands, such as CCL3 and CCL5, which are involved in the recruitment of immune cells to sites of inflammation.

By blocking the interaction between CD191 and its ligands, Mirostipen Biosimilar – Anti-CD191 reduces the recruitment of inflammatory cells, thereby decreasing inflammation and tissue damage. Additionally, this antibody may also induce the apoptosis (cell death) of CD191-expressing cells, further reducing the inflammatory response.

Applications of Mirostipen Biosimilar – Anti-CD191

Mirostipen Biosimilar – Anti-CD191 has shown potential in the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. These diseases are characterized by an excessive immune response and tissue damage, which can be mitigated by targeting CD191.

In preclinical studies, Mirostipen Biosimilar – Anti-CD191 has demonstrated efficacy in reducing inflammation and disease severity in animal models of rheumatoid arthritis and psoriasis. In addition, this therapeutic antibody has also shown promising results in a mouse model of multiple sclerosis, reducing the infiltration of immune cells into the central nervous system and improving disease outcomes.

Research Grade Availability

Mirostipen Biosimilar – Anti-CD191 is currently available in research grade for use in preclinical studies and research purposes. This allows for further investigation of its potential in treating various inflammatory and autoimmune diseases, as well as the development of more potent and specific versions of the antibody for clinical use.

Conclusion

In summary, Mirostipen Biosimilar – Anti-CD191 is a novel biosimilar antibody with a unique structure and mechanism of action. Its ability to target CD191, a key player in the inflammatory response, makes it a promising therapeutic option for various inflammatory and autoimmune diseases. With further research and development, this antibody has the potential to improve the lives of patients suffering from these debilitating conditions.